Abstract
Gestational diabetes mellitus (GDM), a heritable metabolic disorder and the most common pregnancy-related condition, remains understudied regarding its genetic architecture and its potential for early prediction using genetic data. Here we conducted genome-wide association studies on 116,144 Chinese pregnancies, leveraging their non-invasive prenatal test (NIPT) sequencing data and detailed prenatal records. We identified 13 novel loci for GDM and 111 for five glycemic traits, with minor allele frequencies of 0.01-0.5 and absolute effect sizes of 0.03-0.62. Approximately 50% of these loci were specific to GDM and gestational glycemic levels, distinct from type 2 diabetes and general glycemic levels in East Asians. A machine learning model integrating polygenic risk scores (PRS) and prenatal records predicted GDM before 20 weeks of gestation, achieving an AUC of 0.729 and an accuracy of 0.835. Shapley values highlighted PRS as key contributors. This model offers a cost-effective strategy for early GDM prediction using clinical NIPT.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Guangdong Basic and Applied Basic Research Foundation (2022B1515120080 and 2020A1515110859), the Shenzhen Science and Technology Program (20220818100717002), the Shenzhen Health Elite Talent Training Project, the Economic and Technological Development Special Fundation of Shenzhen Longgang District (LGKCYLWS2022008), the National Natural Science Foundation of China (31900487 and 82203291),National Natural Science Foundation of China (82203291),Shenzhen Health Elite Talent Training Project,the Economic and Technological Development Special Fundation of Shenzhen Longgang District （LGKCYLWS2022008）
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Ethics Committee of the School of Public Health (Shenzhen), Sun Yat-Sen University (approval number: 2021. No.8), as well as the Institutional Review Boards of Shenzhen Baoan Women and Children Hospital (approval number: LLSC2021-04-01-10-KS) and Longgang District Maternity and Child Healthcare Hospital (approval number: LGFYYXLLL-2022-024). Data collection was authorized by the Human Genetic Resources Administration of China (HGRAC).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos